ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0334

Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records

Zara Izadi1, Alfredo Aguirre2, Christine Anastasiou2, Julia Kay3, Gabriela Schmajuk4 and Jinoos Yazdany5, 1University of California San Francisco, San Francisco, CA, 2University of California, San Francisco, San Francisco, CA, 3UCSF, San Francisco, CA, 4UCSF / SFVA, San Francisco, CA, 5UCSF, San Rafael, CA

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, classification criteria, Epidemiology, Lupus nephritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Real-world data could provide valuable information in the study of lupus nephritis (LN), if these cases could be reliably identified. A lack of ability to perform chart reviews has prohibited a detailed understanding of under-coding of LN diagnoses in EHRs. In this study we aimed to determine the current performance of ICD9/10 codes for identifying prevalent LN, using a manual chart review of the EHR as gold standard.

Methods: We used structured data and notes from EHRs of two large health systems in the San Francisco Bay Area and included patients with ≥1 ICD9/10 codes for SLE from June 2012 to Jan 2022. Prevalent LN was defined as any documentation of LN diagnosis in EHR notes which included active LN and LN in remission. We used a combination of text extraction using regular expressions (of “lupus nephritis” and related terms) and a manual structured chart review on 100 patients from each health system to identify LN cases (Figure 1). The chart review was performed by two rheumatologists with an independent rheumatologist adjudicating any disagreements. For each health system, in order to enrich chart review with sufficient LN cases, we included a random sample of 50 patients and a random sample of 50 “possible” LN patients defined as either 1) any renal ICD codes, or 2) ≥1 urine protein to creatinine ratio ≥0.5 mg/mg. Patients were categorized into ‘no LN’, ‘definite LN’ (biopsy report and LN Class III, IV, or V verified), ‘potential LN’ (no biopsy report but physician diagnosed LN), and ‘diagnostic uncertainty’ (physician states LN is possible). For each health system separately, we determined the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of ≥1 ICD9/10 codes and ≥2 ICD9/10 codes ≥30 days apart, for identifying patients with a “strict” (definite LN) or an “inclusive” (definite LN, potential LN, or diagnostic uncertainty) definition of LN.

Results: The random samples for manual chart review were selected from a total of 4,522 patients from both health systems (Table 1). A majority of chart-reviewed cases had definite LN and were identified with the ICD10 codes M32.14 or M32.15, or ICD9 code 710.0 in combination with ICD9 codes 583.81, 581.81, or 583.89. The total number of chart-reviewed cases with a strict and inclusive definition of LN was 34 and 41 (out of 100) from health system A, and 40 and 46 (out of 100) from health system B. The sensitivity of ≥1 ICD9/10 codes based on a strict and inclusive definition of LN was 55.9% and 51.2% at health system A, and 72.5% and 65.2% at health system B. The specificity, PPV and NPV of ≥1 ICD9/10 codes based on a strict definition of LN was 93.9%, 82.6%, and 80.5% at health system A and 91.6%, 85.3%, and 83.3% at health system B. The diagnostic criterion of ≥1 ICD9/10 codes used with the strict definition of LN yielded the highest accuracy in both health systems (Table 2).

Conclusion: Despite good specificity and PPV, the sensitivity of diagnosis codes for identification of LN was low, ranging from 42.5% to 72.5%. Performance of diagnosis codes varied by diagnostic criteria, definition of LN, and across health systems. Further work is needed to address under-coding of LN diagnoses in order to identify incident and prevalent cases of LN.

Supporting image 1

Overview of methodology for the gold-standard set development.

Supporting image 2

Characteristics of the underlying population.

Supporting image 3

Performance of diagnosis codes for identifying prevalent LN patients. Strict: Definite LN only; Inclusive: definite LN, potential LN, or diagnostic uncertainty; PPV: positive predictive value; NPV: negative predictive value.


Disclosures: Z. Izadi, None; A. Aguirre, None; C. Anastasiou, None; J. Kay, None; G. Schmajuk, None; J. Yazdany, AstraZeneca, AstraZeneca, Bristol-Myers Squibb(BMS), Gilead, Pfizer, Aurinia.

To cite this abstract in AMA style:

Izadi Z, Aguirre A, Anastasiou C, Kay J, Schmajuk G, Yazdany J. Performance of Diagnosis Codes for Identification of Prevalent Lupus Nephritis Patients from Electronic Health Records [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/performance-of-diagnosis-codes-for-identification-of-prevalent-lupus-nephritis-patients-from-electronic-health-records/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-diagnosis-codes-for-identification-of-prevalent-lupus-nephritis-patients-from-electronic-health-records/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology